Abstract:Nuclear factor-κB (NF-κB) and interleukin-6 (IL-6), a NF-κB downstream mediator, play a central role in inflammatory response and vascular cell growth. Inflammation and a dysregulated immune response are found in many forms of severe pulmonary arterial hypertension (PAH), but how the NF-κB pathway contributes to PAH development is unclear. The SU5416 and chronic hypoxia (Su/Hx) rat PAH model is, like severe human PAH, characterized by obliterative pulmonary vascular lesions and right ventricular failure. We hypothesized that activation of the classical NF-κB pathway in severe PAH promotes ongoing vascular lesion cell apoptosis and proliferation, as well as dysregulation of the immune system. We aimed to determine the role of NF-κB in severe PAH induced by Su/Hx in rats. PAH was induced by a single injection of SU5416 and exposure to chronic hypoxia. Su/Hx rats were treated from day 1-21 with the NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) and/or anti-IL-6 antibody. After hemodynamic assessment at day 21, cytokine/chemokine expression, NF-κB activation, lymphocyte accumulation, as well as pulmonary arterial cell apoptosis and proliferation were evaluated by Western blot, Flow cytometry and immunohistochemistry. The classical NF-κB pathway was activated in pulmonary arterial lesions SuHx rats. NF-κB inhibition with PDTC prevented the development of pulmonary arterial obliteration and in part PAH without reducing muscularization. However, the elevated lung levels of IL-6 were not reduced in PDTC-treated SuHx animals. Apoptosis of pulmonary artery wall cells and pulmonary arterial obliteration was prevented by PDTC or by PDTC+IL-6 inhibition and partially by IL-6 inhibition alone. Pulmonary arterial media wall thickness was not affected by any of these treatments. In Su/Hx rats, CD4 + T cells were reduced and perivascular CD8 + T lymphocytes and CD45RA + B lymphocytes were increased. NF-κB inhibition promoted immune regulation by increasing the number of perivascular CD4 + T cells and reducing the number of perivascular CD8 + T lymphocytes and CD45RA + B lymphocytes. Inhibition of NF-κB may represent a therapeutic option for pulmonary arterial obliteration via reduced vessel wall cell apoptosis and improved immune regulation.

The Role of Regulatory T Cells in Pulmonary Arterial Hypertension

The Role of TGF-β or BMPR2 Signaling Pathway-Related Mirna in Pulmonary Arterial Hypertension and Systemic Sclerosis

Regulatory role of autophagy in development of pulmonary artery hypertension

Epigenetic Regulation of Pulmonary Arterial Hypertension

Suppression of Tissue Inhibitors of Metalloproteinases May Reverse Severe Pulmonary Arterial Hypertension.

The role of chemokines and chemokine receptors in pulmonary arterial hypertension

Regulatory T Cell-Related Gene Indicators in Pulmonary Hypertension

The role of immune cells in the pathogenesis of connective tissue diseases-associated pulmonary arterial hypertension

Inhibition of CRTH2-mediated Th2 Activation Attenuates Pulmonary Hypertension in Mice

Abstract 9814: Nf-?B Inhibition Prevents Vascular Obliteration and Improves Immune Regulation in Severe Pulmonary Arterial Hypertension

Role of the Immune System Elements in Pulmonary Arterial Hypertension

Immunity and Inflammation in Pulmonary Arterial Hypertension: From Pathophysiology Mechanisms to Treatment Perspective

Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management

Role of macrophages in pulmonary arterial hypertension

Regulatory B cells protect against chronic hypoxia‐induced pulmonary hypertension by modulating the Tfh/Tfr immune balance

Identification of immune‐associated signatures and potential therapeutic targets for pulmonary arterial hypertension

The Impact of Highly Selective Thoracic Sympathectomy on the Progression of Monocrotaline-induced Pulmonary Arterial Hypertension in Rats

Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension

Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression

Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept